#Hong Kong #RNA Therapy #Ribo Life Science

Ribo Life Science Debuts on Hong Kong Stock Exchange

On January 10, 2026, Ribo Life Science Co., Ltd. (stock code: 06938.HK) celebrated a significant milestone as it successfully launched on the Hong Kong Stock Exchange. Recognized as a leader in small interfering RNA (siRNA) therapies, Ribo's listing not only underscores the company's growth but also highlights the increasing investor interest in the biopharmaceutical sector across China.

In its impressive initial public offering (IPO), Ribo issued a total of 31,610,400 shares at a price of 57.97 HKD per share, raising over 1.8 billion HKD in gross revenue. The IPO was met with overwhelming demand, surpassing expectations by over 100 times for the subscription and 16.7 times internationally. This strong interest reflects the global investors' confidence in the siRNA industry's potential, particularly in Ribo's capabilities.

The funds raised from the IPO will be allocated toward four key areas:
1. Accelerating global multicenter clinical trials for essential products;
2. Supporting the preclinical and clinical development of its product pipeline;
3. Enhancing the platform support for siRNA and other technological advancements;
4. Strengthening the working capital to ensure efficient corporate operation.

Dr. Zicai Liang, the founder, president, and CEO of Ribo, expressed his appreciation during the opening remarks: "The listing on the Hong Kong Stock Exchange marks an important chapter in Ribo's journey. We are sincerely grateful to our global investors for their trust and support. Looking forward, we will leverage international capital markets to expedite global clinical development and commercialization of our siRNA therapies, further strengthen our technological foundation, provide innovative therapies to patients worldwide, and create sustainable value for our shareholders."

Ribo has successfully built a comprehensive research and development platform with independent intellectual property rights. Its innovative RiboGalSTART™ delivery technology, targeting the liver, has advanced several products into Phase II clinical trials. The company boasts R&D centers in Suzhou, Beijing, and Gothenburg, Sweden, and maintains a global R&D network that supports the full drug development process—from discovery to worldwide clinical trials.

The IPO was supported by prominent financial institutions, including China International Capital Corporation and Citigroup, which played crucial roles in facilitating Ribo's entry into the capital markets. Ribo Life Science is dedicated to offering revolutionary therapeutic solutions to patients worldwide through continuous innovation in small interfering RNA (siRNA) technologies.

As the global biopharmaceutical landscape continues to evolve, Ribo's successful listing is a promising indicator of the growing confidence in this sector, and its commitment to advancing healthcare through innovative treatments is set to redefine the potential for RNA-based therapies.